

## Introducing Antisense Oligonucleotides into Cells

Mark Behlke, M.D., Ph.D.<sup>1</sup>, Eric J. Devor, Ph.D.<sup>1</sup>, and John Goodchild Ph.D.<sup>2</sup>

<sup>1</sup>Molecular Genetics and Bioinformatics

Integrated DNA Technologies

<sup>2</sup>Worcester Foundation for Experimental Biology

The choice of sequence and chemistry of the antisense oligonucleotide is crucial to the success of any given experiment (Stein and Cheng, 1993). In addition to choosing the optimal chemistry, the researcher must decide upon a target site within the gene of interest. This entails looking at the possible cross-reactivity with non-target genes, as well as considering the conformational and thermodynamic characteristics of both the site and the probe. In addition, the investigator must carefully check the antisense oligonucleotide to make certain it doesn't contain sequences that might evoke biological responses unrelated to the down regulation of the targeted gene. These issues are discussed in more detail in IDT's Technical Report, "Designing Antisense Oligonucleotides."

**TABLE 1**

### Successful Antisense Experimental Design

(Phillips and Zhang, 2000)

---

Unique DNA Sequence  
Efficient Cellular Uptake  
Minimal Nonspecific Binding  
Target Specific Hybridization  
Non-toxic Antisense Construct  
Minimal Inflammatory or Immune Response  
Demonstrate Reduction in Target mRNA  
Appropriate Controls

Once the antisense sequence is specified, the investigator must then design the controls. It is important to assess any unforeseen effects of the antisense oligonucleotide. The researcher must also consider the best way to deliver the probe to the internal workings of the cell where the probe can down regulate the gene of interest.

### Control Sequences

Experienced researchers have learned that antisense oligonucleotides can incite unexpected biological and pharmacological effects, underscoring the need for good controls. Researchers wishing to use antisense as a tool are not always aware of the

pitfalls, and thus many studies are still poorly controlled. The behavior of an oligonucleotide in a cell or other biological environment may be influenced by its base composition and by global properties such as conformation. No perfect control exists; therefore multiple controls should be used (Stein and Krieg, 1994). Controls are divided into four types:

- Oligonucleotide sequences that maintain structural features such as hairpins but have different base compositions from the antisense.
- Scrambled oligonucleotide sequences that have the same base compositions as the antisense but not the same structural features, such as hairpins.
- Antisense oligonucleotide sequences with one or more mismatches to show whether the target is selectively hybridized.
- Use of cell lines in which the target gene is mutated or deleted.

Using a variety of controls strengthens confidence in interpreting antisense experiments. Moreover, results will have the greatest believability when the levels of the target RNA and its expressed protein are directly measured.

### **Oligonucleotide Uptake**

**Receptor-mediated endocytosis.** Oligonucleotide entry into living cells has been shown to occur through receptor-mediated endocytosis. Small oligonucleotides are taken up more rapidly than long oligonucleotides. This uptake can be competitively inhibited by other small oligonucleotides, especially if they contain a 5' phosphate. Uptake is temperature-dependent, occurring more rapidly at 37°C than at 4°C. Modifying the oligonucleotide can change its uptake efficiency. Tissue culture cells bind and internalize phosphorothioate-modified oligonucleotides better than they do phosphodiester oligonucleotides or methylphosphonates (Zhao, Matson, Herrera *et al.*, 1993). Oligonucleotide uptake by this mechanism is inefficient and seems to deposit the oligonucleotides into nonnuclear intracellular compartments that are largely inaccessible to RNA (Jaroszewski, Syi, Ghosh *et al.*, 1993). As a general rule, it appears more effective to use methods to directly facilitate oligonucleotide entry into the cell. Some investigators have suggested that any effects shown by endocytosed oligonucleotides may have been induced through sequence-independent mechanisms (Bonham, Brown, Boyd *et al.*, 1995).

**Microinjection.** Microinjecting oligonucleotides into cells results in rapid accumulation of the oligonucleotide in the nucleus (Chin, Green, Zon *et al.*, 1990; Fisher, Terhorst, Cao *et al.*, 1993). It is important to note that when delivering an oligonucleotide directly into cells, the researcher can limit toxicity by controlling the purity of the preparation. One method used to ensure purity for microinjection is to use a series of HPLC and gel

filtration steps to further purify the oligonucleotide (Woolf, Jennings, Rebagliati *et al.*, 1990).

**Lipids.** Microinjection apparatus isn't always available to users and cannot be used in most *in vivo* studies. Cationic lipids are commonly used to facilitate the entry of a variety of compounds — including antisense oligonucleotides — into living cells (Juliano and Akhtar, 1992). The cationic detergent DOTMA is commercially marketed for use as a transfection aid (lipofectin, Invitrogen Life Technologies). In one series of experiments, lipofectin at 8  $\mu\text{M}$  was shown to enhance the entry of an 18-mer phosphorothioate oligonucleotide into HUVEC cells by 20-fold and to effect a 1000-fold increase in biological antisense activity. Lipofectin became toxic when increased to 16  $\mu\text{M}$ .

Cationic lipids do not appear to directly transport DNA into the cellular cytoplasm. Rather, a complex multistage process occurs. First, a DNA:cationic lipid complex is internalized in an endosome. Anionic lipids on the cytoplasmic face of the endosome fuse with the cationic transfection agent, and the oligonucleotide is displaced into the cytoplasm (Zelphati and Szoka, Jr., 1996). Oligonucleotides that have been introduced through lipofectin-induced uptake are diffusely distributed in the cytoplasm and the nucleus (Dheur and Saison-Behmoaras, 2000). This distribution presumably results in greater oligonucleotide bioavailability and subsequent enhancement in antisense effect (Bennett, Chiang, Chan *et al.*, 1992) (Chiang, Chan, Zounes *et al.*, 1991) (Colige, Sokolov, Nugent *et al.*, 1993).

Cationic lipids should be used with caution and appropriate controls; growth of HCT116 colon tumor cells is inhibited by DOTMA in a linear dose-dependent fashion (Yeoman, Danels, and Lynch, 1992). Cationic detergents may not be useful in promoting oligonucleotide uptake in all cell types. In one study, keratinocytes were found to take up phosphorothioate oligonucleotides equally well both with and without lipofectin (Nestle, Mitra, Bennett *et al.*, 1994). Lipid-based agents other than lipofectin have been used to enhance oligonucleotide uptake into cells. Different cell lines and different forms of DNA (single-stranded oligonucleotides, circular plasmids, etc.) may each have a different optimal lipid agent. Further, different chemically modified forms of DNA may require reoptimization of the transfection procedure (Conrad, Behlke, Jaffredo *et al.*, 1998). The precise agent used, the ratio of DNA:lipid, and the liposome complexation volumes may require optimization (Staggs, Burton, and Deftos, 1996). Invitrogen sells a kit (PerFect Lipid Transfection Kit), which is convenient to use for this purpose (Griffiths, Russell, Froning *et al.*, 1997). It should also be noted that not all lipid-based agents can be used in the presence of serum (Lewis, Lin, Kothavale *et al.*, 1996).

Encapsulation of concentrated oligonucleotides in lipid vesicles by the minimum volume entrapment method can protect oligonucleotides from attack by nucleases in serum and deliver them intact into cells. In one described method, cardiolipin, phosphatidylcholine, and cholesterol were mixed at a 0.5:10:7 molar ratio, and combined with an antisense oligonucleotide. This formulation resulted in a final product that contained 60–70  $\mu\text{g}$  oligonucleotide/mg lipid. Natural phosphodiester oligonucleotides are stable in serum for days when encapsulated in such liposomes and liposomal delivery increased

oligonucleotide uptake about 20-fold into MOLT3 cells and resulted in diffuse cytoplasmic and nuclear localization (Thierry and Dritschilo, 1992).

Liposomes can be made for this application by a number of slightly different techniques (Hope, Bally, Webb *et al.*, 1985). Moreover, liposomes can be modified in a number of ways that enhance their ability to deliver nucleic acids into living cells. The addition of certain viral coat proteins can increase the efficiency of fusion and uptake severalfold. Polyoma virus pseudocapsids have been shown to be efficient carriers of nucleic acids into mammalian cells. These transfection vehicles contain pure viral VP1 protein produced *in vitro* using the baculovirus insect cell system and are free of other viral proteins and genetic material. Their use can enhance delivery of transfected DNA many fold over unmodified liposomes (Forstova, Krauzewicz, Sandig *et al.*, 1995).

Even with the use of lipid agents to promote transfection, oligonucleotide entry into individual cells can vary more than 100-fold. Vaughn (1995) used a fluorescence-activated cell sorter to assess cell-to-cell variability. Cells were incubated with fluorescein-labeled phosphorothioate antisense oligonucleotides targeting the ERBB2 message. Cells were later incubated with a cascade blue-labeled anti-ERBB2 antibody. Evaluation of dual-fluorescence spectra indicated that cells having higher levels of antisense oligonucleotide had much lower levels of ERBB2 protein. Potent antisense effect was seen with approximately  $10^7$  antisense molecules per cell.

**Liposome modifications.** It is possible to take advantage of natural import pathways to introduce foreign material into living cells. Vitamins such as folic acid are actively imported by such a mechanism (Leamon and Low, 1991). Folate-binding protein (FBP) resides in the cell membrane and is responsible for the active uptake of folate via receptor-mediated endocytosis. This transport system is very efficient and has a  $K_d$  in the nanomolar range. If liposomes are tagged with folate using a long 250-Å polyethylene glycol (PEG) spacer, steric hindrance is minimized and the liposomes are imported (Lee and Low, 1994). PEG addition also seems to prolong liposome survival *in vivo* by interfering with their clearance by the reticuloendothelial system. Oligonucleotides packaged into liposomes and delivered to cells are protected from serum nucleases. Unmodified phosphodiester oligonucleotides encapsulated in folate-PEG liposomes have been shown to invoke antisense activity equivalent to that of similarly encapsulated phosphorothioate-modified oligonucleotides.

**Other methods of facilitated entry.** One group pretreated cells with streptolysin *O* and found a 100-fold increase in oligonucleotide permeation with minimal cellular toxicity (Spiller and Tidd, 1995). The antennapedia homeodomain protein is translocated through cell membranes and targeted to nuclear localization. A 16-amino acid peptide fragment from the third helix has been shown to confer this property to the protein (Derossi, Joliot, Chassaing *et al.*, 1994). Investigators have used this peptide coupled to an antisense oligonucleotide to facilitate direct entry of the oligonucleotide into the nucleus, giving high efficiency of penetration with low dosing. Use of this agent was compatible with serum-containing tissue culture medium and seemed to protect the oligonucleotide from nucleolytic degradation, enabling the use of phosphodiester DNA as an antisense agent

(Troy, Derossi, Prochiantz *et al.*, 1996). This peptide is commercially available with a sulfhydryl-modifier enabling its attachment to a SH-modified oligonucleotide; Qbiogene sells it under the trade name penetratin. Glycoprotein tagging has also been used to modify oligonucleotides to target them for uptake into specific cell types such as hepatocytes (Wu and Wu, 1992); (Lu, Fischman, Jyawook *et al.*, 1994).

***In vivo* delivery systems.** Proteins derived from the coat of Sendai viruses are known to promote fusion of lipid bilayers. In one series of experiments, oligonucleotides were packaged in liposomes complexed with coat proteins derived from the hemagglutinating virus of Japan (HVJ, a Sendai family virus) and were infused into rat carotid arteries where they fused with the vascular endothelium and neointima. The oligonucleotides curtailed intimal hyperplasia following vascular injury, which was the expected antisense effect (Morishita, Gibbons, Ellison *et al.*, 1993; Morishita, Gibbons, Ellison *et al.*, 1994). It is possible to use fluorescein-conjugated antisense oligonucleotides to track their fate *in vivo*. Oligonucleotides delivered via liposome encapsulation can be detected in the nucleus for up to two weeks after administration (Morishita and others, 1994). Liposome preparations are commonly used for *in vivo* delivery of many classes of compounds (Lasic, 1996). Interestingly, however, uptake into tissues in living organisms using intravenous, subcutaneous, or intraperitoneal injections have been higher than expected from experience with cell culture (Agrawal, 1996) (Matteucci and Wagner, 1996).

## Conclusion

Antisense technology represents a powerful technology for functional genomics and rational therapeutics. A number of parameters need to be considered when designing Antisense experiments; these include oligonucleotide sequence, structure and purity, secondary structure of the target RNA, mechanism of action and the process chosen to introduce the Antisense oligonucleotide into the cell. Cellular uptake of phosphorothioate oligonucleotides is highly variable depending on a number of conditions including cell type, kinetics of uptake, tissue culture conditions and oligonucleotide chemical class. (Crooke, 1991) (Crooke, Grillone, Tendolkar *et al.*, 1994). Conclusions about *in vitro* uptake must be made carefully and generalizations are impossible (Crooke, 2000).

## References

Agrawal,S. (1996) Antisense oligonucleotides: towards clinical trials *Trends Biotechnol.* **14**: 376-387.

Bennett,C.F., Chiang,M.Y., Chan,H., Shoemaker,J.E., and Mirabelli,C.K. (1992) Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides *Mol.Pharmacol.* **41**: 1023-1033.

Bonham,M.A., Brown,S., Boyd,A.L., Brown,P.H., Bruckenstein,D.A., Hanvey,J.C., Thomson,S.A., Pipe,A., Hassman,F., Bisi,J.E., and . (1995) An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers *Nucleic Acids Res.* **23**: 1197-1203.

- Chiang, M.Y., Chan, H., Zounes, M.A., Freier, S.M., Lima, W.F., and Bennett, C.F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms *J.Biol.Chem.* **266**: 18162-18171.
- Chin, D.J., Green, G.A., Zon, G., Szoka, F.C., Jr., and Straubinger, R.M. (1990) Rapid nuclear accumulation of injected oligodeoxyribonucleotides *New Biol.* **2**: 1091-1100.
- Colige, A., Sokolov, B.P., Nugent, P., Baserga, R., and Prockop, D.J. (1993) Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells *Biochemistry* **32**: 7-11.
- Conrad, A.H., Behlke, M.A., Jaffredo, T., and Conrad, G.W. (1998) Optimal lipofection reagent varies with the molecular modifications of the DNA *Antisense Nucleic Acid Drug Dev.* **8**: 427-434.
- Crooke, R.M. (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides *Anticancer Drug Des* **6**: 609-646.
- Crooke, S.T. (2000) Progress in antisense technology: the end of the beginning *Methods Enzymol.* **313** : 3-45.
- Crooke, S.T., Grillone, L.R., Tendolkar, A., Garrett, A., Fratkin, M.J., Leeds, J., and Barr, W.H. (1994) A pharmacokinetic evaluation of <sup>14</sup>C-labeled afovirsen sodium in patients with genital warts *Clin.Pharmacol.Ther.* **56**: 641-646.
- Derossi, D., Joliot, A.H., Chassaing, G., and Prochiantz, A. (1994) The third helix of the Antennapedia homeodomain translocates through biological membranes *J.Biol.Chem.* **269**: 10444-10450.
- Dheur, S., Saison-Behmoaras, T.E. (2000) Polyethyleneimine-mediated transfection to improve antisense activity of 3'-capped phosphodiester oligonucleotides *Methods Enzymol.* **313**: 56-73.
- Fisher, T.L., Terhorst, T., Cao, X., and Wagner, R.W. (1993) Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells *Nucleic Acids Res.* **21**: 3857-3865.
- Forstova, J., Krauzewicz, N., Sandig, V., Elliott, J., Palkova, Z., Strauss, M., and Griffin, B.E. (1995) Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells *Hum.Gene Ther.* **6**: 297-306.
- Griffiths, T., Russell, M., Froning, K., Brown, B.D., Scanlon, S.M., Almazan, M., Marcil, R., and Hoeffler, J.P. (1997) The PerFect lipid optimizer kit for maximizing lipid-mediated transfection of eukaryotic cells *Biotechniques* **22**: 982-987.
- Hope, M.J., Bally, M.B., Webb, G., and Cullis, P.R. (1985) Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume, and ability to maintain a membrane potential. *Biochem.Biophys.Acta* **812**: 55.

- Jaroszewski, J.W., Syi, J.L., Ghosh, M., Ghosh, K., and Cohen, J.S. (1993) Targeting of antisense DNA: comparison of activity of anti-rabbit beta-globin oligodeoxyribonucleotides phosphorothioates with computer predictions of mRNA folding *Antisense Res.Dev.* **3**: 339-348.
- Juliano, R.L., Akhtar, S. (1992) Liposomes as a drug delivery system for antisense oligonucleotides *Antisense Res.Dev.* **2**: 165-176.
- Lasic, D.D. (1996) Doxorubicin in sterically stabilized liposomes *Nature* **380**: 561-562.
- Leamon, C.P., Low, P.S. (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis *Proc.Natl.Acad.Sci.U.S.A* **88**: 5572-5576.
- Lee, R.J., Low, P.S. (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis *J.Biol.Chem.* **269**: 3198-3204.
- Lewis, J.G., Lin, K.Y., Kothavale, A., Flanagan, W.M., Matteucci, M.D., DePrince, R.B., Mook, R.A., Jr., Hendren, R.W., and Wagner, R.W. (1996) A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA *Proc.Natl.Acad.Sci.U.S.A* **93**: 3176-3181.
- Lu, X.M., Fischman, A.J., Jyawook, S.L., Hendricks, K., Tompkins, R.G., and Yarmush, M.L. (1994) Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake *J.Nucl.Med.* **35**: 269-275.
- Matteucci, M.D., Wagner, R.W. (1996) In pursuit of antisense *Nature* **384**: 20-22.
- Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., von der, L.H., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V.J. (1994) Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides *J.Clin.Invest* **93**: 1458-1464.
- Morishita, R., Gibbons, G.H., Ellison, K.E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., and Dzau, V.J. (1993) Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia *Proc.Natl.Acad.Sci.U.S.A* **90**: 8474-8478.
- Nestle, F.O., Mitra, R.S., Bennett, C.F., Chan, H., and Nickoloff, B.J. (1994) Cationic lipid is not required for uptake and selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes *J.Invest Dermatol.* **103**: 569-575.
- Phillips, M.I., Zhang, Y.C. (2000) Basic principles of using antisense oligonucleotides in vivo *Methods Enzymol.* **313**: 46-56.
- Spiller, D.G., Tidd, D.M. (1995) Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O *Antisense Res.Dev.* **5**: 13-21.

Staggs,D.R., Burton,D.W., and Deftos,L.J. (1996) Importance of liposome complexing volume in transfection optimization *Biotechniques* **21**: 792, 784, 796, 798.

Stein,C.A., Cheng,Y.C. (1993) Antisense oligonucleotides as therapeutic agents--is the bullet really magical? *Science* **261**: 1004-1012.

Stein,C.A., Krieg,A.M. (1994) Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides *Antisense Res.Dev.* **4**: 67-69.

Thierry,A.R., Dritschilo,A. (1992) Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity *Nucleic Acids Res.* **20**: 5691-5698.

Troy,C.M., Derossi,D., Prochiantz,A., Greene,L.A., and Shelanski,M.L. (1996) Downregulation of Cu/Zn superoxide dismutase leads to cell death via the nitric oxide-peroxynitrite pathway *J.Neurosci.* **16**: 253-261.

Woolf,T.M., Jennings,C.G., Rebagliati,M., and Melton,D.A. (1990) The stability, toxicity and effectiveness of unmodified and phosphorothioate antisense oligodeoxynucleotides in *Xenopus* oocytes and embryos *Nucleic Acids Res.* **18**: 1763-1769.

Wu,G.Y., Wu,C.H. (1992) Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides *J.Biol.Chem.* **267**: 12436-12439.

Yeoman,L.C., Danels,Y.J., and Lynch,M.J. (1992) Lipofectin enhances cellular uptake of antisense DNA while inhibiting tumor cell growth *Antisense Res.Dev.* **2**: 51-59.

Zelphati,O., Szoka,F.C., Jr. (1996) Mechanism of oligonucleotide release from cationic liposomes *Proc.Natl.Acad.Sci.U.S.A* **93**: 11493-11498.

Zhao,Q., Matson,S., Herrera,C.J., Fisher,E., Yu,H., and Krieg,A.M. (1993) Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides *Antisense Res.Dev.* **3**: 53-66.